Physician profile
Michael S Croft
NPI 1720007313
$10,456.60
in general payments reported to CMS, 2019-2025
10 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $239 · 2021: $229 · 2022: $119 · 2023: $138 · 2024: $8,364 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,240 · Food and Beverage: $388 · Entertainment: $54.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,240.00 |
| Food and Beverage | $387.59 |
| Entertainment | $54.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $8,240.00 | 2024 | |
| Alcon Vision LLC | $1,459.12 | 2019-2025 | Total30, Precision7, Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $249.00 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $241.20 | 2019-2025 | |
| Coopervision INC. | $96.41 | 2020-2025 | Myday Contact Lens |
| Optos, INC. | $54.46 | 2024-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Bausch & Lomb Americas INC. | $32.02 | 2022-2024 | Xiidra, Miebo |
| Heru, INC. | $25.57 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Croft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.